Next Article in Journal
Cervical Cancer Prevention in Racially Disparate Rural Populations
Next Article in Special Issue
Targeting Aberrant Sialylation to Treat Cancer
Previous Article in Journal
Pathological Mechanisms and Therapeutic Targets for Trigeminal Neuropathic Pain
Previous Article in Special Issue
Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends
Review

Early Stage Glycosylation Biomarkers in Alzheimer’s Disease

1
Institute of Technology Sligo, Ash Lane, F91 YW50 Sligo, Ireland
2
Cellular Health and Toxicology Research Group, Institute of Technology Sligo, Ash Lane, F91 YW50 Sligo, Ireland
3
Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Clinical Translational Research and Innovation Centre, Altnagelvin Area Hospital, Glenshane Road, Derry BT47 6SB, UK
*
Author to whom correspondence should be addressed.
Medicines 2019, 6(3), 92; https://doi.org/10.3390/medicines6030092
Received: 30 June 2019 / Revised: 29 August 2019 / Accepted: 30 August 2019 / Published: 3 September 2019
(This article belongs to the Special Issue Application of Glycobiology in the Treatment of Diseases)
Alzheimer’s disease (AD) is of great cause for concern in our ageing population, which currently lacks diagnostic tools to permit accurate and timely diagnosis for affected individuals. The development of such tools could enable therapeutic interventions earlier in the disease course and thus potentially reducing the debilitating effects of AD. Glycosylation is a common, and important, post translational modification of proteins implicated in a host of disease states resulting in a complex array of glycans being incorporated into biomolecules. Recent investigations of glycan profiles, in a wide range of conditions, has been made possible due to technological advances in the field enabling accurate glycoanalyses. Amyloid beta (Aβ) peptides, tau protein, and other important proteins involved in AD pathogenesis, have altered glycosylation profiles. Crucially, these abnormalities present early in the disease state, are present in the peripheral blood, and help to distinguish AD from other dementias. This review describes the aberrant glycome in AD, focusing on proteins implicated in development and progression, and elucidates the potential of glycome aberrations as early stage biomarkers of AD. View Full-Text
Keywords: Alzheimer’s; biomarker; glycosylation; Aβ; tau Alzheimer’s; biomarker; glycosylation; ; tau
Show Figures

Figure 1

MDPI and ACS Style

Regan, P.; McClean, P.L.; Smyth, T.; Doherty, M. Early Stage Glycosylation Biomarkers in Alzheimer’s Disease. Medicines 2019, 6, 92. https://doi.org/10.3390/medicines6030092

AMA Style

Regan P, McClean PL, Smyth T, Doherty M. Early Stage Glycosylation Biomarkers in Alzheimer’s Disease. Medicines. 2019; 6(3):92. https://doi.org/10.3390/medicines6030092

Chicago/Turabian Style

Regan, Patricia, Paula L. McClean, Thomas Smyth, and Margaret Doherty. 2019. "Early Stage Glycosylation Biomarkers in Alzheimer’s Disease" Medicines 6, no. 3: 92. https://doi.org/10.3390/medicines6030092

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop